272 related articles for article (PubMed ID: 37371079)
1. PD-L1's Role in Preventing Alloreactive T Cell Responses Following Hematopoietic and Organ Transplant.
Handelsman S; Overbey J; Chen K; Lee J; Haj D; Li Y
Cells; 2023 Jun; 12(12):. PubMed ID: 37371079
[TBL] [Abstract][Full Text] [Related]
2. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.
Saha A; O'Connor RS; Thangavelu G; Lovitch SB; Dandamudi DB; Wilson CB; Vincent BG; Tkachev V; Pawlicki JM; Furlan SN; Kean LS; Aoyama K; Taylor PA; Panoskaltsis-Mortari A; Foncea R; Ranganathan P; Devine SM; Burrill JS; Guo L; Sacristan C; Snyder NW; Blair IA; Milone MC; Dustin ML; Riley JL; Bernlohr DA; Murphy WJ; Fife BT; Munn DH; Miller JS; Serody JS; Freeman GJ; Sharpe AH; Turka LA; Blazar BR
J Clin Invest; 2016 Jul; 126(7):2642-60. PubMed ID: 27294527
[TBL] [Abstract][Full Text] [Related]
3. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
[TBL] [Abstract][Full Text] [Related]
4. Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80.
Cassady K; Martin PJ; Zeng D
Front Immunol; 2018; 9():3061. PubMed ID: 30622541
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of T-cell-suppressive PD-L1
Baur R; Karl F; Böttcher-Loschinski R; Stoll A; Völkl S; Gießl A; Flamann C; Bruns H; Schlötzer-Schrehardt U; Böttcher M; Schewe DM; Fischer T; Jitschin R; Mackensen A; Mougiakakos D
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898735
[TBL] [Abstract][Full Text] [Related]
6. Donor T cell STAT3 deficiency enables tissue PD-L1-dependent prevention of graft-versus-host disease while preserving graft-versus-leukemia activity.
Li Q; Wang X; Song Q; Yang S; Wu X; Yang D; Marié IJ; Qin H; Zheng M; Nasri U; Kong X; Wang B; Lizhar E; Cassady K; Tompkins J; Levy D; Martin PJ; Zhang X; Zeng D
J Clin Invest; 2023 Aug; 133(15):. PubMed ID: 37526084
[TBL] [Abstract][Full Text] [Related]
7. Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group.
Kasai S; Itonaga H; Niino D; Miyoshi H; Kato T; Imanishi D; Fujioka M; Furumoto T; Sato S; Sawayama Y; Taguchi J; Imaizumi Y; Hata T; Yoshida S; Moriuchi Y; Ohshima K; Miyazaki Y
Int J Hematol; 2020 Oct; 112(4):524-534. PubMed ID: 32588395
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 serves as a double agent in separating GVL from GVHD.
Brennan TV; Yang Y
J Clin Invest; 2017 May; 127(5):1627-1630. PubMed ID: 28414300
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Ameliorates Murine Acute Graft-Versus-Host Disease by Suppressing Effector But Not Regulatory T Cells Function.
Tang L; Ma S; Gong H; Wang J; Xu Y; Wu D; Sun A
Arch Immunol Ther Exp (Warsz); 2019 Jun; 67(3):179-187. PubMed ID: 30927016
[TBL] [Abstract][Full Text] [Related]
10. Potential Role of the PD-1/PD-L1 Axis in the Immune Regulation of Chronic GVHD.
Klobuch S; Weber D; Holler B; Herr W; Holler E; Wolff D
Oncol Res Treat; 2017; 40(7-8):447-450. PubMed ID: 28683452
[TBL] [Abstract][Full Text] [Related]
11. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
[TBL] [Abstract][Full Text] [Related]
12. The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease.
Al-Chaqmaqchi H; Sadeghi B; Abedi-Valugerdi M; Al-Hashmi S; Fares M; Kuiper R; Lundahl J; Hassan M; Moshfegh A
PLoS One; 2013; 8(4):e60367. PubMed ID: 23593203
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.
Juchem KW; Sacirbegovic F; Zhang C; Sharpe AH; Russell K; McNiff JM; Demetris AJ; Shlomchik MJ; Shlomchik WD
J Immunol; 2018 Jan; 200(2):834-846. PubMed ID: 29212909
[TBL] [Abstract][Full Text] [Related]
14. Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway.
Molina MS; Hoffman EA; Stokes J; Kummet N; Simpson RJ; Katsanis E
PLoS One; 2022; 17(8):e0273075. PubMed ID: 35980974
[TBL] [Abstract][Full Text] [Related]
15. Human amnion-derived mesenchymal stem cells attenuate xenogeneic graft-versus-host disease by preventing T cell activation and proliferation.
Tago Y; Kobayashi C; Ogura M; Wada J; Yamaguchi S; Yamaguchi T; Hayashi M; Nakaishi T; Kubo H; Ueda Y
Sci Rep; 2021 Jan; 11(1):2406. PubMed ID: 33510297
[TBL] [Abstract][Full Text] [Related]
16. PD-1 and PD-L1 expression in cardiac transplantation.
Bishawi M; Bowles D; Pla MM; Oakes F; Chiang Y; Schroder J; Milano C; Glass C
Cardiovasc Pathol; 2021; 54():107331. PubMed ID: 33737091
[TBL] [Abstract][Full Text] [Related]
17. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes.
Okiyama N; Katz SI
J Autoimmun; 2014 Sep; 53():1-9. PubMed ID: 25047812
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
[TBL] [Abstract][Full Text] [Related]
20. Blockade of PD-1/PD-L1 increases effector T cells and aggravates murine chronic graft-versus-host disease.
Liang Y; Shen J; Lan Q; Zhang K; Xu Y; Duah M; Xu K; Pan B
Int Immunopharmacol; 2022 Sep; 110():109051. PubMed ID: 35850051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
